摘要
本文用酶联免疫吸附分析 (ELISA) ,测定各种妇科疾病患者 10 0例治疗前后血清CA12 5水平 ,CA12 5大于 35kU/L为诊断卵巢癌的阳性阈值 ,结果显示卵巢癌阳性率为 95 % (19/2 0 ) ;子宫肌瘤为 16 .7% (6 /36 ) ;卵巢良性畸胎瘤 2 0 % (3/15 ) ;其他妇科疾病为 13 .8% (4/2 9)。以CA12 5大于 6 5kU/L为诊断卵巢癌阳性阈值 ,除卵巢癌组外则不存在假阳性。 2 0例卵巢癌患者经手术或放化疗治疗后 ,其中 16例CA12 5小于 35kU/L ,其余良性妇科疾病患者经治疗后 ,虽然CA12 5有不同程度的降低 ,但降低幅度不大。提示测定妇科疾病患者血清CA12 5对卵巢癌诊断、疗效评价及预后有较高的价值。
To study the clinical significance of serum CA125 in patients with ovarian cancer, the serum CA125 levels in 100 patients with gynecologic disease before and after treatment were examined by the method of enzyme linked immunosorbent assay(ELISA). With the positive standard of serum CA125 level >35kU/L, the positive rates of ovarian cancer, hysteromyoma, benign teratoma and other benign gynecologic disease were 95%(19/20), 16.7%(6/36), 20%(3/15) and 13.8%(4/29) respectively. But serum CA125 level >65kU/L, there was no positive rates except ovarian cancer group. Of the 20 ovarian cancer patients studied, serum CA125 level in 16 cases decreased significantly (<35kU/L) after chemical and surgical therapy. Serum CA125 is useful in the diagnosis and evaluation of treatment and prognosis for ovarian cancer.
出处
《标记免疫分析与临床》
CAS
2001年第3期142-144,共3页
Labeled Immunoassays and Clinical Medicine
